samarium Sm 153 lexidronam pentasodium

RADIATION5 trials

Sponsors

Louisiana State University Health Sciences Center Shreveport, Oncotherapeutics, National Cancer Institute (NCI), Mayo Clinic

Conditions

Breast CancerMultiple Myeloma and Plasma Cell NeoplasmProstate Cancer

Phase 1

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

TerminatedNCT00003086

Louisiana State University Health Sciences Center ShreveportBreast Cancer

Start: 1997-03-31End: 2001-01-28Target: 12Updated: 2020-07-14

Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

CompletedNCT00316940

OncotherapeuticsMultiple Myeloma and Plasma Cell Neoplasm

Start: 2005-12-31End: 2011-02-28Target: 36Updated: 2013-09-20

Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

CompletedNCT00478075

Mayo ClinicMultiple Myeloma and Plasma Cell Neoplasm

Start: 2005-09-30End: 2009-06-30Target: 50Updated: 2011-05-11

Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

CompletedNCT00602706

Mayo ClinicMultiple Myeloma and Plasma Cell Neoplasm

Start: 2000-01-31End: 2010-07-31Target: 76Updated: 2011-05-16

Phase 2

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

CompletedNCT00450619

National Cancer Institute (NCI)Prostate Cancer

Start: 2007-02-28End: 2012-11-30Updated: 2017-01-04